COMPANY

Aulos Bioscience

Keywords: antibody monoclonal antibody oncology solid tumor Cutaneous Melanoma Non-Small Cell Lung Cancer AU-007

Location: Larkspur, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Deal Merck deal · amount not disclosed · announced May 15, 2024 Company release ↗
Source quote
- May 15, 2024 · Company release ↗
  “Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA”

From the company’s own releases; this list is partial. All raises and deals

Apr 4, 2022 Trial start Phase 1/Phase 2: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer source ↗

Feb 28, 2027 (ESTIMATED) · Phase 1/Phase 2 · Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer · NCT05267626

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT05267626	Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer	Phase 1/Phase 2	Recruiting	Apr 4, 2022	Feb 28, 2027 (estimated)